Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05283226RecruitingPhase 2
Oral anti-cancer pill plus paclitaxel after immunotherapy failure
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Fullerton, CaliforniaAges 18 years+ - NCT05318469RecruitingPhase 1/Phase 2
Ivermectin with immunotherapy for metastatic triple-negative breast cancer
This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.
Los Angeles, CaliforniaAges 18 years+ - NCT05396872Recruiting
Decision-making study about gene testing for advanced prostate cancer
This study looks at how Veterans with advanced prostate cancer make decisions about gene testing and possible targeted treatments, and how patients and caregivers understand the information. It may help by improving decision support for people facing germline and tumor testing choices.
San Francisco, CaliforniaAges 18 years+ - NCT05452213RecruitingPhase 4
Study patterns of ribociclib response and resistance in breast cancer
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
Erlangen, BavariaAges 18 years+ - NCT05462236RecruitingPhase 2
Study drug AUM001 with immunotherapy or chemotherapy for metastatic colon cancer
This Phase 2 trial tests AUM001 (a targeted drug) combined with either pembrolizumab (an immunotherapy) or irinotecan (a chemotherapy) in people with metastatic colorectal cancer. It aims to shrink tumors and improve outcomes when standard treatments have already been tried.
Camperdown, New South WalesAges 18 years+ - NCT05472948RecruitingPhase 2
Testing surufatinib plus immunotherapy with capecitabine for bowel cancer
This Phase 2 study tests a combination of anti-cancer drugs (surufatinib, immunotherapy, and capecitabine) to treat cancer that has spread to other parts of the body. It’s for people whose small intestine or appendix adenocarcinoma has progressed after earlier treatment, aiming to shrink tumors and improve control of the disease.
Guangzhou, GuangdongAges 18–70 - NCT05524584RecruitingPhase 2
Anastrozole, fulvestrant, and abemaciclib for hormone-positive breast cancer
This trial tests whether combining three medicines can better control hormone-receptor–positive, HER2-negative metastatic breast cancer that cannot be cured with surgery or radiation. It may help shrink tumors and slow disease growth compared with standard hormone therapy approaches.
Orange, CaliforniaAges 18 years+ - NCT05526443Recruiting
Registry study for advanced pancreatic cancer treatment patterns
This registry collects information about people with advanced pancreatic cancer who are receiving first-line palliative treatment. It helps doctors understand which treatment choices are used and how people do over time.
Graz, StyriaAges 18 years+ - NCT05570825RecruitingPhase 2
Study drug SX-682 with pembrolizumab for advanced lung cancer
This trial tests SX-682 plus pembrolizumab (an immunotherapy) to treat metastatic or recurrent non-small cell lung cancer (NSCLC). It aims to see how well the combination works and whether it can shrink or control the cancer in people whose tumors have enough PD-L1.
Seattle, WashingtonAges 18 years+ - NCT05651828RecruitingEarly Phase 1
Tested adaptive dosing of vismodegib for advanced skin cancer
This trial tests an adaptive (adjusted) dosing plan using vismodegib for people with advanced basal cell carcinoma. It may help control the cancer while balancing side effects, and your team will closely monitor how your tumors respond.
Tampa, FloridaAges 18 years+ - NCT05655247Recruiting
Comparing two gum treatments for multiple exposed tooth roots
This trial compares two types of gum surgery to cover exposed tooth roots when you have multiple adjacent gum recessions. It aims to find which approach works best for root coverage and long-term gum health.
TarantoAges Any age - NCT05655949RecruitingPhase 2
Y-90 radiation plus immunotherapy and chemo for bile duct cancer
This trial studies whether combining Y-90 liver radiation with an immunotherapy drug (durvalumab) and chemo (gemcitabine and cisplatin) can better control locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help shrink tumors and slow disease growth, depending on how well the treatment works for your cancer type and overall health.
Boston, MassachusettsAges 18 years+ - NCT05663710RecruitingPhase 1/Phase 2
Study of 177Lu antibody and medicines for first advanced kidney cancer
This trial tests a new combination of targeted medicines (including 177Lu girentuximab) plus immunotherapy to treat people with advanced clear cell kidney cancer who have not had prior systemic (whole-body) treatment. It aims to shrink tumors and control disease by attacking cancer in multiple ways.
Houston, TexasAges 18 years+ - NCT05665361RecruitingPhase 1/Phase 2
Testing palbociclib plus sasanlimab for advanced kidney cancers
This study tests a combination of two medicines—palbociclib and sasanlimab—in people with advanced clear cell or papillary kidney cancer. It’s mainly designed to check safety (and early signs of how well the treatment may work) in these cancer types.
Bethesda, MarylandAges 18–100 - NCT05725200RecruitingPhase 2
Personalized treatment plan for metastatic colon or rectal cancer
This Phase 2 trial tests an individualized treatment chosen from your tumor’s lab testing (genetic and RNA profile plus a drug-sensitivity test from your tumor cells). It may help by matching you to targeted anti-cancer drugs that are most likely to work for your specific cancer.
OsloAges 18 years+ - NCT05727176RecruitingPhase 2
Futibatinib for advanced bile duct cancer with FGFR2 changes
This trial tests futibatinib, a targeted pill, in people with advanced (unresectable) or metastatic bile duct cancer that has an FGFR2 fusion or rearrangement. It may help shrink tumors after standard chemotherapy has stopped working.
La Jolla, CaliforniaAges 18 years+ - NCT05746208RecruitingPhase 2
Lenvatinib plus pembrolizumab for advanced grade 3 NET tumors
This trial studies lenvatinib plus pembrolizumab to treat well-differentiated grade 3 neuroendocrine tumors (NETs) that cannot be fully removed by surgery or are locally advanced. It aims to shrink the tumor or slow its growth after the disease shows progression.
San Francisco, CaliforniaAges 18 years+ - NCT05766748RecruitingPhase 1/Phase 2
Azeliragon trial for pancreatic cancer after prior treatments failed
This trial tests azeliragon in people whose pancreatic cancer has spread or grown locally and who did not respond well to earlier chemotherapy. It aims to see whether the drug can help control the cancer and be tolerated after prior treatment.
Los Angeles, CaliforniaAges 18–80 - NCT05776524RecruitingPhase 2
Radiofrequency heat treatment for pancreas cancer spread to other organs
This Phase 2 trial tests whether a device that delivers carefully timed “radiofrequency heat” through the body can slow or control metastatic (spread) pancreatic cancer. You may qualify if you have newly diagnosed metastatic pancreatic cancer and can meet safety and blood-test requirements.
Winston-Salem, North CarolinaAges 18 years+ - NCT05808634RecruitingPhase 1
Testing an investigational drug for advanced lung or gut cancer
This Phase 1 trial tests BA3182, an investigational medicine, in people with advanced adenocarcinoma that cannot be removed by surgery. The goal is to see how the treatment works and whether it’s tolerated, and it may offer an option when standard options have been limited.
Irvine, CaliforniaAges 18 years+ - NCT05816655RecruitingPhase 2
Test two hormone treatment combinations for metastatic breast cancer
This Phase 2 study compares two combinations of hormone-blocking drugs plus an anti-cancer targeted pill to see which works better for hormone-receptor positive, HER2-negative metastatic breast cancer. It may help by finding a more effective treatment plan when the cancer has spread.
SeoulAges 19–80 - NCT05832827RecruitingPhase 2
First treatment combo for thymic cancer using pembrolizumab plus drugs
This Phase 2 study tests a first (initial) treatment combination of pembrolizumab with three other drugs (carboplatin, paclitaxel, and lenvatinib) for advanced or recurrent thymic carcinoma. It aims to shrink tumors and improve control of the cancer when standard chemotherapy has not yet been tried for your situation.
Chūō, TokyoAges 18 years+ - NCT05904964RecruitingPhase 3
Targeted drug for hormone-positive, HER2-low metastatic breast cancer
This Phase 3 trial tests disitamab vedotin (a targeted drug) in people with hormone receptor–positive, HER2-low metastatic breast cancer that can’t be cured with surgery or radiation. It aims to see whether the drug can control the cancer better than current standard care.
Guangzhou, GuangdongAges 18–70 - NCT05929885RecruitingPhase 2
Genotype-guided chemo for metastatic pancreatic cancer
This trial tests a chemo plan that includes different drugs and adjusts the irinotecan dose based on a patient’s genetic test (UGT1A1). It’s designed for people with pancreatic cancer that has spread or cannot be removed with surgery.
SingaporeAges 21–99
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,366 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.